Aspirin labeling for M-I prevention
This article was originally published in The Tan Sheet
Executive Summary
FDA has enlisted the Aspirin Foundation of America to coordinate submissions of certain foreign studies that looked at aspirin for the prevention of cardiovascular events following an acute myocardial infarction, according to an agency memo of an April 26 meeting between AFA and FDA. Once the data are submitted in proper form, FDA said it will begin working on a notice that would propose prescription labeling for the prophylactic use of aspirin.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning